Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage biotech; raised $305M Series F (Jan 2026) for AI-optimized peptides targeting intracellular cancer proteins previously considered undruggable; oncology-first pipeline
Parabilis Medicines is a clinical-stage biotechnology company applying AI to the design of peptide-based therapeutics targeting proteins previously considered undruggable, with a primary focus on oncology. The company was founded on the insight that AI-optimized peptides — short chains of amino acids — can be engineered to reach and modulate intracellular protein targets that small molecules and biologics cannot access. Parabilis uses proprietary computational platforms to design, screen, and optimize peptide candidates with improved cell permeability, stability, and target selectivity.\n\nThe company's pipeline is centered on cancer proteins that drive tumor growth but lack conventional binding pockets for small molecule inhibition. Parabilis's AI-designed peptides are engineered to penetrate cancer cells and disrupt these oncogenic interactions, potentially unlocking entirely new therapeutic options for patients with tumors driven by these targets. The approach also has potential applications in other diseases where intracellular protein-protein interactions are central to pathology.\n\nParabilis raised $305M in a Series F round in January 2026, one of the largest biotech fundraises of that period. The financing was designed to advance its lead programs through clinical development and expand its pipeline of AI-designed peptide candidates. With over $300M in fresh capital, Parabilis is one of the most heavily funded companies in the emerging AI peptide therapeutics space, positioning it to compete with both traditional peptide drug developers and newer AI-native biotech platforms.
SF YC S23 doctor booking with upfront cost guarantees via ML price prediction; $2.3M Pacific 8/YC seed Dec 2023 solving 57% surprise bills and 38% delayed care competing with Zocdoc for healthcare price transparency booking.
Certainly Health is a San Francisco-based healthcare price transparency marketplace — backed by Y Combinator (S23) with $2.3 million in seed funding in December 2023 from Pacific 8 Ventures, Y Combinator, institutional investors, and angels — providing patients with a doctor booking platform that shows upfront out-of-pocket costs using machine learning to predict and guarantee healthcare spending before appointments, addressing the surprise medical bill crisis where 57% of Americans have received unexpected bills and 38% delay care due to cost uncertainty. Founded in 2023 by Daryl Sew and Kevin Chiu (Stanford graduate, former Uber engineer, and Uber Health founding member who grew that program to $100 million in 2 years), Certainly Health enables patients with insurance to book doctors while seeing the actual cost they will owe — not the sticker price.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.